In-patient characteristics of peripheral artery disease in Germany

医学 截肢 动脉疾病 间歇性跛行 风险因素 外围设备 内科学 跛行 疾病 血管疾病 人口 外科 环境卫生
作者
Alexander Block,Jeanette Köppe,Jannik Feld,Leonie Kühnemund,Christiane Engelbertz,Lena Makowski,Nasser Malyar,Joachim Gerß,Holger Reinecke,Eva Freisinger
出处
期刊:VASA [Hogrefe Publishing Group]
标识
DOI:10.1024/0301-1526/a001099
摘要

Summary: Background: Peripheral artery disease (PAD) frequently leads to hospital admission. Sex related differences in in-patient care are a current matter of debate. Patients and methods: Data were provided from the German national in-patient sample provided by the Federal Bureau of Statistics (DESTATIS). Trends on risk profiles, therapeutic procedures, and outcomes were evaluated from 2014 until 2019 stratified by sex and PAD severity. Results: Two-thirds of an annual >191,000 PAD in-patient cases applied to male sex. Chronic limb-threatening ischemia (CLTI) was recorded in 49.6% of male and 55.2% of female cases (2019). CLTI was as a major risk factor of in-hospital amputation (OR 229) and death (OR 10.5), whereas endovascular revascularisation (EVR) with drug-coated devices were associated with decreased risk of in-hospital amputation (OR 0.52; all p<0.001). EVR applied in 47% of CLTI cases compared to 71% in intermittent claudication (IC) irrespective of sex. In-hospital mortality was 4.3% in male vs. 4.8% in female CLTI cases, minor amputations 18.4% vs. 10.9%, and major amputation 7.5% vs. 6.0%, respectively (data 2019; all p<0.001). After adjustment, female sex was associated with lower risk of amputation (OR 0.63) and death (OR 0.96) during in-patient stay. Conclusions: Male PAD patients were twice as likely to be admitted for in-patient treatment despite equal PAD prevalence in the general population. Among in-patient cases, supply with invasive therapy did not relevantly differ by sex, however is strongly reduced in CLTI. CLTI is a major risk factor of adverse short-term outcomes, whereas female sex was associated with lower risk of in-patient amputation and/or death.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
yangyangyang发布了新的文献求助10
刚刚
siccy完成签到 ,获得积分10
刚刚
图南关注了科研通微信公众号
1秒前
我是老大应助Mrrr采纳,获得10
1秒前
ZTT发布了新的文献求助10
1秒前
调皮的凝旋完成签到,获得积分10
1秒前
JiangY完成签到,获得积分10
1秒前
妮妮爱smile完成签到,获得积分10
2秒前
咕噜仔发布了新的文献求助10
2秒前
3秒前
研友_VZG7GZ应助King16采纳,获得10
3秒前
lyn发布了新的文献求助10
3秒前
瑰夏完成签到,获得积分20
3秒前
喜洋洋发布了新的文献求助10
3秒前
ZL发布了新的文献求助10
3秒前
zhang发布了新的文献求助10
3秒前
3秒前
顺利的爆米花完成签到 ,获得积分10
4秒前
沉静秋尽完成签到,获得积分10
4秒前
大个应助沉静的颦采纳,获得10
4秒前
657完成签到 ,获得积分10
4秒前
4秒前
执念完成签到 ,获得积分10
5秒前
ECCE713完成签到,获得积分10
5秒前
小刺完成签到,获得积分10
5秒前
sweetbearm应助zxl采纳,获得10
5秒前
优秀的盼夏完成签到,获得积分10
6秒前
传奇3应助沉敛一生采纳,获得10
6秒前
科研通AI5应助咕噜仔采纳,获得50
6秒前
lm完成签到,获得积分20
6秒前
FFF发布了新的文献求助10
7秒前
小二郎应助哈哈采纳,获得10
7秒前
乐乐应助juan采纳,获得10
8秒前
txyouniverse完成签到 ,获得积分10
8秒前
CodeCraft应助纷花雨采纳,获得10
8秒前
小十二完成签到,获得积分10
8秒前
Tianxu Li发布了新的文献求助10
9秒前
月白完成签到,获得积分10
9秒前
淡淡de橙子完成签到,获得积分10
10秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527699
求助须知:如何正确求助?哪些是违规求助? 3107752
关于积分的说明 9286499
捐赠科研通 2805513
什么是DOI,文献DOI怎么找? 1539954
邀请新用户注册赠送积分活动 716878
科研通“疑难数据库(出版商)”最低求助积分说明 709759